Trial
NCT00391066
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Biogen
Collaborators
—
Condition
Chronic Lymphocytic Leukemia
Intervention
FCR + Lumiliximab
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-02